A pilot study to evaluate the effects of Cl esterase inhibitor on the toxicity of high-dose interleukin 2
1994

Effects of Cl Esterase Inhibitor on IL-2 Toxicity

Sample size: 6 publication Evidence: low

Author Information

Author(s): A.C. Ogilvie, J.W. Baars, A.J.M. Eerenberg, C.E. Hack, H.M. Pinedo, L.G. Thijs, J. Wagstaff

Primary Institution: Free University Hospital, Amsterdam, The Netherlands

Hypothesis

Can Cl esterase inhibitor administration reduce the toxicity associated with high-dose interleukin 2 treatment?

Conclusion

Cl esterase inhibitor administration during high-dose IL-2 treatment is safe and may help reduce IL-2-induced toxicity.

Supporting Evidence

  • IL-2-induced hypotension was equivalent in both treatment groups.
  • Complement activation was less after IL-2 + C1-INH compared to standard IL-2.
  • No side effects were observed from C1-INH administration.
  • Weight gain was significantly greater during the experimental and historical-control courses than during the self-control course.
  • Total C1-INH levels increased significantly during the experimental course.

Takeaway

This study looked at whether a medicine called Cl esterase inhibitor could make another medicine, interleukin 2, less harmful. It found that using Cl esterase inhibitor was safe and might help reduce side effects.

Methodology

Six patients received high-dose IL-2 with Cl esterase inhibitor, and results were compared to historical controls and self-control courses.

Potential Biases

Potential biases due to the open-label design and small number of participants.

Limitations

Small sample size and lack of a double-blind design.

Participant Demographics

Patients included both males and females with renal cell carcinoma and melanoma, aged 35 to 57 years.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication